Janux director granted RSUs, 15.5K options
Janux Therapeutics director Vickie L. Capps received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Janux Therapeutics director Vickie L. Capps received new equity awards. She was granted 5,500 restricted stock units, each convertible into one share of common stock, increasing her direct holdings to 79,598 shares. She also received options on 15,500 shares at an exercise price of $13.66 per share, vesting over 12 months and fully by the next annual stockholder meeting, subject to continued service.
Insider Trade Summary
Grant/Award: 21,000 shares
Grant/Award
2 txns
Insider
CAPPS VICKIE L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 15,500 contracts (Direct);
Common Stock — 79,598 shares (Direct)
Footnotes (2)
- F1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
- F2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
Key Figures
RSU grant size: 5,500 units
Options granted: 15,500 shares
Option exercise price: $13.66 per share
+3 more
6 metrics
RSU grant size
5,500 units
Restricted stock units awarded to director
Options granted
15,500 shares
Stock options on common stock
Option exercise price
$13.66 per share
Strike price for new stock options
Shares held after grant
79,598 shares
Common stock directly owned post-award
Option expiration date
June 10, 2036
End of option exercise period
RSU vesting date
June 11, 2027
Or earlier next annual stockholder meeting
Key Terms
restricted stock units ("RSUs"), contingent right, continuous service, Stock Option (right to buy), +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"each of which represents a contingent right to receive one share of the Issuer's common stock"
continuous service financial
"in each case, subject to the Reporting Person's continuous service on such date"
Stock Option (right to buy) financial
"Stock Option (right to buy) listed as a derivative security transaction"
vest in equal monthly installments financial
"The shares subject to the option will vest in equal monthly installments over the 12 months"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Janux Therapeutics (JANX) director Vickie L. Capps receive in this Form 4?
Vickie L. Capps received equity compensation consisting of 5,500 restricted stock units and stock options on 15,500 shares. Both awards relate to Janux Therapeutics common stock and were granted as part of her role as a director, not as open-market transactions.
What are the key terms of the RSU grant reported for JANX director Capps?
The 5,500 RSUs each represent a contingent right to one JANX common share. They will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to Vickie L. Capps maintaining continuous service with Janux Therapeutics through that vesting date.
What are the terms of the Janux Therapeutics stock options granted to Vickie L. Capps?
Capps received options for 15,500 shares of Janux Therapeutics common stock at a $13.66 exercise price. These options vest in equal monthly installments over 12 months after June 11, 2026 and will be fully vested by the next annual stockholder meeting, subject to continued service.
When do the Janux Therapeutics stock options granted to Capps expire?
The stock options granted to Vickie L. Capps expire on June 10, 2036. She can exercise them at $13.66 per share once vested, subject to the vesting schedule and her continued service with Janux Therapeutics through the relevant vesting dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates